Dave Ricks, CEO of Eli Lilly | The All-In Interview

(0:00) Friedberg welcomes Eli Lilly CEO Dave Ricks (2:06) The obesity problem: a global chronic health epidemic (13:07) The history of discovering GLP-1s (20:38) Impact of GLP-1s on different human functions (27:09) Understanding the commercial aspect of drug discovery, pricing for GLP-1 drugs (33:11) Responding to criticism and research of GLP-1 dependency (40:04) Stock performance, dealing with political pressure related to successful drugs (47:19) Eli Lilly's portfolio of drugs outside of GLP-1s, what science Dave is excited about (56:09) Scaling and impacting culture at a 100+ year-old company Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg Intro Video Credit: https://x.com/TheZachEffect Referenced in the show: https://www.google.com/finance/quote/LLY:NYSE https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/Estat-adults-fig.png https://www.pbs.org/newshour/politics/fda-approves-new-version-of-diabetes-drug-mounjaro-to-be-sold-for-weight-loss https://www.cnn.com/2024/01/08/health/weight-loss-drug-insurance-denials/index.html https://i.insider.com/638f471e57aefa0018eb9a3d?width=800&format=jpeg&auto=webp https://x.com/EconomyApp #allin #tech #news